Key takeaways
- Semax is H-Met-Glu-His-Phe-Pro-Gly-Pro-OH, a synthetic analogue of the ACTH 4–10 fragment, according to FDA staff.
- Of 210 PubMed records on Semax (November 2026), 153 involve rats or mice; its human studies are few and mostly small, and none is registered on ClinicalTrials.gov.
- FDA staff found insufficient evidence of effectiveness for the three uses they evaluated, and insufficient clinical information to characterise its safety.
- HHS named Semax in a draft, non-binding 2026 compounding policy, which is not an approval; it read the safety record differently from FDA staff, who found too little clinical information to characterise it.
- It is not named in Australia’s Poisons Standard or on WADA’s 2026 and 2027 Lists, and neither absence means it is approved or permitted.
01Semax at a glance
The short version, dated 18 November 2026. Every line is sourced at the end of the page.
| Question | Semax |
|---|---|
| What it is | A synthetic peptide of seven amino acids, Met-Glu-His-Phe-Pro-Gly-Pro (C37H51N9O10S, 813.9 g/mol), which FDA staff describe as an analogue of the ACTH 4–10 fragment. |
| Other names | “Semax (heptapeptide)” on FDA’s compounding page; CAS 80714-61-0. An acetate salt also exists. |
| Evidence tier | Mostly T3: 153 of 210 PubMed records involve rats or mice. T2 for people: mostly small studies; none we could read describes random assignment, and none is registered on ClinicalTrials.gov. |
| Human studies | FDA staff found eight references that gave it to people: 33 to 47 healthy adults, 69 adults with medical conditions and 451 children. They found insufficient evidence of effectiveness for the three uses they evaluated. |
| United States | Not FDA-approved. In compounding Category 2 from 29 Sep 2023 to 22 Apr 2026, now listed as a nomination withdrawn. Named in HHS’s draft enforcement-discretion policy (30 Oct 2026), which is not binding and not an approval. |
| United Kingdom | No result on the emc medicines database (18 Nov 2026). |
| Australia | Not named in the Poisons Standard October 2026 (text searched 18 Nov 2026). |
| WADA | Not named on the 2026 or 2027 List; whether class S0 applies is unresolved (see below). |
02What is Semax?
Semax is a short synthetic peptide of seven amino acids: methionine, glutamic acid, histidine, phenylalanine, proline, glycine and proline. FDA staff describe it as a synthetic analogue of ACTH 4–10, a fragment of adrenocorticotropic hormone (ACTH). The two sequences differ in their last three amino acids; Semax ends in Pro-Gly-Pro, which is thought to make it more resistant to breakdown by enzymes. Citing a 2013 review, FDA staff write that Semax lacks the hormone’s corticotropic activity, its effect on the adrenal glands.
Most of the research is in animals. Of the 210 PubMed records with Semax in the title or abstract (18 November 2026), 153 involve rats or mice, and 89 are Russian-language articles. FDA staff summarise rodent studies in several areas and call the mechanisms “poorly understood”.
Semax is not the same molecule as Selank, another seven-amino-acid peptide, and their US histories differ: see the Selank guide and Semax and Selank research.
03What human studies of Semax exist, and what did FDA staff conclude?
Few and mostly small studies, none registered on ClinicalTrials.gov (searched 18 November 2026). The table shows who took part, the design and what was measured. It does not report what the authors concluded.
| Study | People | Design | What was measured |
|---|---|---|---|
| Koroleva et al., 1996 | 37 people with migraine or facial nerve pain | Open-label, no control group (FDA staff) | Pain rating scales; nerve-response recordings |
| Gusev et al., 1997 | 30 patients in the acute period of ischaemic stroke; 80 comparison patients on standard care | Added to standard care; the abstract does not describe how patients were assigned | Clinical rating scales; EEG mapping; evoked potentials |
| Serdiuk et al., 2007 | 27 people with motor neuron disease | Open-label | Needle EMG; disease rating scales; quality of life |
| Gusev et al., 2018 | 110 adults after ischaemic stroke | Early or late rehabilitation groups, each split into with and without Semax; assignment not described in the abstract | Blood BDNF levels; motor strength; Barthel index of everyday activities |
| Panikratova et al., 2020 | 52 healthy participants | Semax, Selank or placebo | Resting brain connectivity on fMRI, before and twice in the 20 minutes after |
| Two meeting abstracts (FDA staff) | 120 children with depression; 331 children with tics or Tourette syndrome | Semax alongside other treatments; full studies not available | Not available |
Across the eight references FDA staff reviewed, Semax was given to 33 to 47 healthy adults, 69 adults with medical conditions and 451 children. Three were meeting abstracts, and in several Semax was given with other treatments, “making it difficult to determine the contribution of semax to any effects seen”. FDA staff did not consider Russian-language references that lacked English translations, which leaves out both stroke studies above.
FDA staff’s verdict. For the three uses they could evaluate (cerebral ischaemia, migraine and trigeminal neuralgia), FDA staff found “insufficient evidence” of effectiveness: only two references were available, with “insufficient details on the design and conduct of the studies”. How to weigh studies like these: evidence grades.
04What have regulators said about Semax safety?
FDA staff concluded there is “insufficient clinical information to characterize the safety profile” of Semax, and that its use in compounding “may raise safety concerns”. HHS read the same record differently.
FDA. Most of the human references “did not discuss safety”; one reported no adverse events. FAERS, FDA’s adverse-event database, held one report through 3 December 2025: a consumer described eye pain and burning after using a Semax product bought online, and a hospitalisation, with the pain unresolved when reported a year later. FDA staff found no published case reports. They flagged two signals: a meeting abstract describing possible anti-clotting properties, which “raises concern about the risk of bleeding”, and a mouse finding that Semax increased amphetamine-induced dopamine release, a response “typically induced by drugs of abuse”. They found no study of its immunogenicity and are “concerned” about it by the routes nominators proposed; FDA’s compounding page says Semax “may pose risk for immunogenicity for certain routes of administration”.
HHS. HHS’s 2026 policy appendix calls CDER’s safety concerns “mechanistic rather than observed”, saying the human record CDER compiled “covers several hundred subjects with no reported adverse outcome” and that “the bleeding and abuse-potential signals have no clinical counterpart in that record”. FDA staff had noted that most of those references did not discuss safety. More: side effects, documented vs unknown.
05Is Semax an approved medicine? Status by country
United States. Semax is not an FDA-approved drug or a component of one, and Drugs@FDA lists no product containing it (18 November 2026). HHS records that it sat in FDA’s compounding Category 2 from 29 September 2023 to 22 April 2026, that CDER recommended against listing either form, and that the July 2026 advisory committee voted in favour of both. FDA’s compounding page now lists “Semax (heptapeptide)” among nominations withdrawn. HHS then named Semax among six peptides in a policy saying it does not intend to pursue enforcement against state-licensed pharmacies, federal facilities and licensed physicians compounding with them, under conditions that include a patient-specific prescription. The Federal Register notice of 30 October 2026 calls it a draft that “is not binding”. It is not an approval. Background: the July 2026 vote and the HHS policy.
United Kingdom. A search of the emc medicines database for Semax returned no results on 18 November 2026. FDA staff found no Semax monograph in the European, Japanese or International Pharmacopoeia. More: are peptides legal in the UK?
Russia. FDA staff wrote that Semax “is a registered drug in Russia”, citing Russia’s state register of medicines, accessed in December 2025. We could not open that register to confirm it (18 November 2026). Research-grade Semax is not that registered medicine.
Australia. Semax is not named in the Poisons Standard October 2026, and not being named does not make it approved or permitted. See are peptides legal in Australia?
Sport. Semax is not named on WADA’s 2026 or 2027 Prohibited List. Class S0 covers any pharmacological substance not addressed elsewhere on the List “and with no current approval by any governmental regulatory health authority for human therapeutic use”, prohibited at all times. Whether S0 reaches Semax depends on an approval status we could not verify, and anti-doping organisations decide. See peptides and anti-doping.
06What we don’t know about Semax
- Any effect in people from a registered, placebo-controlled trial. None is on ClinicalTrials.gov, and FDA staff found insufficient evidence for the uses they reviewed.
- Its safety over months or years, its abuse potential and its bleeding risk. FDA staff found no studies that settle them.
- Which form the human studies used. FDA staff note the references do not say whether they used the free base or a salt.
- Its status in Russia. FDA staff report a registration there; we could not open the register to confirm it.
- What a vial sold as Semax contains. Only that lot’s lab report can show it: how to read a COA.
This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not legal or medical advice.